TY - T1的吸入型皮质类固醇激素和COVID-19: a systematic review and clinical perspective JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01009-2020 VL - 55 IS - 5 SP - 2001009 AU - Halpin, David M.G. AU - Singh, Dave AU - Hadfield, Ruth M. Y1 - 2020/05/01 UR - //www.qdcxjkg.com/content/55/5/2001009.abstract N2 - The current coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, raises important questions as to whether pre-morbid use or continued administration of inhaled corticosteroids (ICS) affects the outcomes of acute respiratory infections due to coronavirus. Many physicians are concerned about whether individuals positive for SARS-CoV-2 and taking ICS should continue them or stop them, given that ICS are often regarded as immunosuppressive. A number of key questions arise. Are people with asthma or COPD at increased risk of developing COVID-19? Do ICS modify this risk, either increasing or decreasing it? Do ICS influence the clinical course of COVID-19? (figure 1). Whether ICS modify the risk of developing COVID-19 or the clinical course of COVID-19 in people who do not have lung disease should also be considered (figure 1).There is no evidence on benefits or harms of inhaled steroids in COVID-19. It is essential that epidemiological studies of COVID-19 include detailed information on comorbidities and prior medication to help answer this question. https://bit.ly/2XVwIsaWe wish to thank Rebecca Decker, Executive Director, Global Initiative for Chronic Obstructive Lung Disease (GOLD) for her support and Wei-jie Guan and Ying Zhong for their help with the papers written in Chinese. ER -